U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H38N6O2
Molecular Weight 466.6189
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TD-2749

SMILES

CC(C)N1N=C(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3CCN4CCN(CC4)C(C)=O)C5=C1C=CC=C5

InChI

InChIKey=ZQMXTDPQEHZTBG-KOUNCHBCSA-N
InChI=1S/C26H38N6O2/c1-18(2)32-24-7-5-4-6-23(24)25(28-32)26(34)27-20-16-21-8-9-22(17-20)31(21)15-12-29-10-13-30(14-11-29)19(3)33/h4-7,18,20-22H,8-17H2,1-3H3,(H,27,34)/t20-,21+,22-

HIDE SMILES / InChI

Molecular Formula C26H38N6O2
Molecular Weight 466.6189
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Tue Oct 22 05:09:48 UTC 2019
Edited
by admin
on Tue Oct 22 05:09:48 UTC 2019
Record UNII
0ZN0AQ6SBV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TD-2749
Common Name English
1H-INDAZOLE-3-CARBOXAMIDE, N-((3-ENDO)-8-(2-(4-ACETYL-1-PIPERAZINYL)ETHYL)-8-AZABICYCLO(3.2.1)OCT-3-YL)-1-(1-METHYLETHYL)-
Systematic Name English
N-((1S,5R)-8-(2-(4-ACETYLPIPERAZIN-1-YL)ETHYL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-1-ISOPROPYL-INDAZOLE-3-CARBOXAMIDE
Systematic Name English
1-ISOPROPYL-1H-INDAZOLE-3-CARBOXYLIC ACID N-(3-ENDO-8-(2-(4-ACETYLPIPERAZIN-1-YL)ETHYL)-8-AZABICYCLO(3.2.1)OCT-3-YL)AMIDE
Systematic Name English
Code System Code Type Description
CAS
863248-59-3
Created by admin on Tue Oct 22 05:09:48 UTC 2019 , Edited by admin on Tue Oct 22 05:09:48 UTC 2019
PRIMARY
DRUG BANK
TD-2749
Created by admin on Tue Oct 22 05:09:48 UTC 2019 , Edited by admin on Tue Oct 22 05:09:48 UTC 2019
PRIMARY Name: TD-2749; Accession Number: DB05905; Type: Small Molecule; Group: Investigational; Description: TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Related Record Type Details
OFF TARGET->NON-INHIBITOR
9% inhibition at 3 MICROMOLAR
IC50
TARGET -> AGONIST
BINDING
Ki
TARGET -> AGONIST
Maximum compound-evoked response 83% expressed as a percentage of the maximum response evoked by 5-HT.
EC50
Related Record Type Details
ACTIVE MOIETY
Class: Gastrokinetic, Irritable bowel syndrome therapy; Mechanism of Action: Serotonin 4 receptor agonist; Highest Development Phase: Discontinued for Gastrointestinal disorders; Most Recent Events: 14 Sep 2007 Discontinued - Phase-I for Gastrointestinal disorders in USA (PO), 06 Sep 2007 GlaxoSmithKline decides not to exercise its option to license TD 2749, 20 Mar 2006 Theravance has completed a phase I trial in Gastrointestinal disorders in USA